SCHEDULE: Lincoln Alternative Strategies Discloses 11.83% Stake in GRI Bio
Beneficial Ownership Disclosure
Lincoln Alternative Strategies LLC has reported a passive beneficial ownership of 11.83% in GRI Bio, Inc., holding 1,197,755 shares of common stock.
Summary
- Lincoln Alternative Strategies LLC has filed a Schedule 13G, indicating beneficial ownership of 1,197,755 shares of GRI Bio, Inc. common stock.
- This ownership represents 11.83% of GRI Bio, Inc.'s outstanding common stock.
- The beneficial ownership percentage is calculated based on 10,121,060 shares of common stock issued and outstanding as of December 19, 2025, as disclosed in GRI Bio, Inc.'s Preliminary Proxy Statement.
- Lincoln Alternative Strategies LLC holds sole voting power and sole dispositive power over all 1,197,755 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of GRI Bio, Inc.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as a significant institutional investor has taken a substantial passive stake, which can be interpreted as a positive signal for the company's valuation and future prospects.
Positives
- A significant institutional investor, Lincoln Alternative Strategies LLC, has taken a substantial passive stake (11.83%) in GRI Bio, Inc., which can be viewed as a vote of confidence in the company's long-term prospects.
Industry Context
This filing indicates a notable institutional investment in GRI Bio, Inc., a company whose name suggests a focus on biotechnology or life sciences. Such disclosures are common in the biotech sector, where institutional investors often take positions based on potential drug pipelines, research advancements, or market opportunities. A significant passive stake by an alternative strategies firm suggests a belief in the company's underlying value without an immediate intent to influence management or strategy.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may instill greater confidence among existing shareholders and potentially attract new investors, possibly leading to increased trading volume or share price stability.
Key Dates
| Date | Description |
|---|---|
| 12/12/2025 | Date of event which required the filing of this statement. |
| 12/19/2025 | Date as of which the issuer's common stock outstanding (10,121,060 shares) was disclosed in its Preliminary Proxy Statement. |
| 12/29/2025 | Date the Schedule 13G was signed by Lincoln Alternative Strategies LLC. |
Keywords
GRI Bio Inc, Lincoln Alternative Strategies, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Equity Stake, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.